{"id":1809,"date":"2023-10-27T12:00:12","date_gmt":"2023-10-27T10:00:12","guid":{"rendered":"https:\/\/dextechmedical.com\/?p=1809"},"modified":"2023-10-26T20:08:25","modified_gmt":"2023-10-26T18:08:25","slug":"interim-report-july-1-september-30-2023","status":"publish","type":"post","link":"https:\/\/dextechmedical.com\/en\/interim-report-july-1-september-30-2023\/","title":{"rendered":"Interim report July 1- September 30, 2023"},"content":{"rendered":"<div class=\"page\" title=\"Page 1\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Summary of the first quarter (2023-07-01 \u2013 2023-09-30)<\/strong><\/p>\n<ul>\n<li>Net sales amounted to MSEK 0,0 (0,0)<\/li>\n<li>Operating profit\/loss amounted to MSEK -1,1 (-0,8)<\/li>\n<li>Earnings per share* SEK -0.05 (-0.04)<\/li>\n<li>Cash and cash equivalents at the end of the period amounted to MSEK 23,6 (25,2)<\/li>\n<\/ul>\n<p>* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 18,485,857. Amounts in brackets refer to the corresponding period last year.<\/p>\n<p><strong>CEO&#8217;s comment<\/strong><\/p>\n<p>The company&#8217;s Phase 1 study regarding OsteoDex&#8217;s treatment of multiple myeloma is underway and patient recruitment is ongoing. Some inclusion criteria have been adjusted which means that more patients can be included.<\/p>\n<p>Principal investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology\/HERM, Karolinska University Hospital, Huddinge. Biomarkers are analysed at the Central Laboratory, Karolinska University Hospital, NKS, Solna. Patients with relapsed\/treatment-resistant disease who have received 1-5 prior lines of therapy are included. The primary objective is to confirm safety and tolerability and as a secondary objective to determine possible response to treatment. Documentation of quality of life will also be done (QoL scores).<\/p>\n<p>Study material, GMP manufactured OsteoDex, is produced by Biovian OY, Turku, Finland and is delivered to the respective hospitals. We are excited to conduct this study.<\/p>\n<p>The company has filed a new patent application with the European Patent Office regarding the GMP production of OsteoDex (GMP = good manufacturing practice). If the application is granted, patent protection will be granted until approximately 2044. We believe that the conditions for approval of the application are very good.<\/p>\n<p>Anders R Holmberg<\/p>\n<p><a href=\"https:\/\/dextechmedical.com\/wp-content\/uploads\/Dextech-Interim-report-July-September-2023.pdf\">Dextech &#8211; Interim report July &#8211; September 2023<\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Summary of the first quarter (2023-07-01 \u2013 2023-09-30) Net sales amounted to MSEK 0,0 (0,0) Operating profit\/loss amounted to MSEK -1,1 (-0,8) Earnings per share* SEK -0.05 (-0.04) Cash and [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-1809","post","type-post","status-publish","format-standard","hentry","category-okategoriserade-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Interim report July 1- September 30, 2023 | DexTech<\/title>\n<meta name=\"description\" content=\"Summary of the first quarter (2023-07-01 \u2013 2023-09-30) Net sales amounted to MSEK 0,0 (0,0) Operating profit\/loss amounted to MSEK -1,1 (-0,8) Earnings\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dextechmedical.com\/?p=1805\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Interim report July 1- September 30, 2023 | DexTech\" \/>\n<meta property=\"og:description\" content=\"Summary of the first quarter (2023-07-01 \u2013 2023-09-30) Net sales amounted to MSEK 0,0 (0,0) Operating profit\/loss amounted to MSEK -1,1 (-0,8) Earnings\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dextechmedical.com\/?p=1805\" \/>\n<meta property=\"og:site_name\" content=\"DexTech\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-27T10:00:12+00:00\" \/>\n<meta name=\"author\" content=\"G\u00f6sta Lundgren\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"G\u00f6sta Lundgren\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dextechmedical.com\/?p=1805\",\"url\":\"https:\/\/dextechmedical.com\/?p=1805\",\"name\":\"Interim report July 1- September 30, 2023 | DexTech\",\"isPartOf\":{\"@id\":\"https:\/\/dextechmedical.com\/#website\"},\"datePublished\":\"2023-10-27T10:00:12+00:00\",\"author\":{\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c\"},\"description\":\"Summary of the first quarter (2023-07-01 \u2013 2023-09-30) Net sales amounted to MSEK 0,0 (0,0) Operating profit\/loss amounted to MSEK -1,1 (-0,8) Earnings\",\"breadcrumb\":{\"@id\":\"https:\/\/dextechmedical.com\/?p=1805#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dextechmedical.com\/?p=1805\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dextechmedical.com\/?p=1805#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/dextechmedical.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Interim report July 1- September 30, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dextechmedical.com\/#website\",\"url\":\"https:\/\/dextechmedical.com\/\",\"name\":\"DexTech\",\"description\":\"Ett svenskt forskningsf\u00f6retag specialiserat p\u00e5 urologisk onkologi fr\u00e4mst prostatacancer\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dextechmedical.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c\",\"name\":\"G\u00f6sta Lundgren\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g\",\"caption\":\"G\u00f6sta Lundgren\"},\"sameAs\":[\"https:\/\/dextechmedical.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Interim report July 1- September 30, 2023 | DexTech","description":"Summary of the first quarter (2023-07-01 \u2013 2023-09-30) Net sales amounted to MSEK 0,0 (0,0) Operating profit\/loss amounted to MSEK -1,1 (-0,8) Earnings","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dextechmedical.com\/?p=1805","og_locale":"en_US","og_type":"article","og_title":"Interim report July 1- September 30, 2023 | DexTech","og_description":"Summary of the first quarter (2023-07-01 \u2013 2023-09-30) Net sales amounted to MSEK 0,0 (0,0) Operating profit\/loss amounted to MSEK -1,1 (-0,8) Earnings","og_url":"https:\/\/dextechmedical.com\/?p=1805","og_site_name":"DexTech","article_published_time":"2023-10-27T10:00:12+00:00","author":"G\u00f6sta Lundgren","twitter_misc":{"Written by":"G\u00f6sta Lundgren","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/dextechmedical.com\/?p=1805","url":"https:\/\/dextechmedical.com\/?p=1805","name":"Interim report July 1- September 30, 2023 | DexTech","isPartOf":{"@id":"https:\/\/dextechmedical.com\/#website"},"datePublished":"2023-10-27T10:00:12+00:00","author":{"@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c"},"description":"Summary of the first quarter (2023-07-01 \u2013 2023-09-30) Net sales amounted to MSEK 0,0 (0,0) Operating profit\/loss amounted to MSEK -1,1 (-0,8) Earnings","breadcrumb":{"@id":"https:\/\/dextechmedical.com\/?p=1805#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dextechmedical.com\/?p=1805"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/dextechmedical.com\/?p=1805#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/dextechmedical.com\/en\/"},{"@type":"ListItem","position":2,"name":"Interim report July 1- September 30, 2023"}]},{"@type":"WebSite","@id":"https:\/\/dextechmedical.com\/#website","url":"https:\/\/dextechmedical.com\/","name":"DexTech","description":"Ett svenskt forskningsf\u00f6retag specialiserat p\u00e5 urologisk onkologi fr\u00e4mst prostatacancer","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dextechmedical.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c","name":"G\u00f6sta Lundgren","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g","caption":"G\u00f6sta Lundgren"},"sameAs":["https:\/\/dextechmedical.com"]}]}},"_links":{"self":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/1809","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/comments?post=1809"}],"version-history":[{"count":1,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/1809\/revisions"}],"predecessor-version":[{"id":1812,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/1809\/revisions\/1812"}],"wp:attachment":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/media?parent=1809"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/categories?post=1809"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/tags?post=1809"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}